{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045860","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.350006+00:00","generated_at":"2026-05-30T00:23:30.081092+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing","bullets":["Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.","Foundation grant of up to ~$10.7M for novel non-hormonal contraceptive and to add Ovaprene Phase 3 sites.","ARPA-H award of $10M for DARE-HPV IND-enabling activities; NICHD grant of $2M for DARE-PTB1.","Ovaprene Phase 3 enrolling at 10 US sites; target ~125 women completing 6 mo by Q2 2025.","Sildenafil Cream Phase 3 discussions with FDA ongoing; each Phase 3 study est. ~$15M direct costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045860","json":"https://secwatch.observer/filing/0001493152-24-045860.json","markdown":"https://secwatch.observer/filing/0001493152-24-045860.md","text":"https://secwatch.observer/filing/0001493152-24-045860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/0001493152-24-045860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:23:30.081092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}